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Identification of a subpopulation of macrophages in mammary
tumor-bearing mice that are neither M1 nor M2 and are less
differentiated
Abstract
Systemic and local immune deficiency is associated with cancer, and the role of M2 tumor-associated
macrophages in this phenomenon is well recognized. However, the immune status of macrophages from
peripheral compartments in tumor hosts is unclear. Peritoneal macrophages (PEM) are derived from
circulating monocytes and recruited to the peritoneal cavity where they differentiate into macrophages.
We have previously shown that PEMs from mice bearing D1-DMBA-3 mammary tumors (T-PEM) are
deficient in inflammatory functions and that this impairment is associated with diminished expression of
transcription factors nuclear factor kappaB and CAAT/enhancer-binding protein. We now provide
evidence that T-PEMs display neither M1 nor M2 phenotypes, yet exhibit deficiencies in the expression
of several inflammatory cytokines and various proinflammatory signaling pathways. Moreover, due to
nuclear factor kappaB down-regulation, increased apoptosis was observed in T-PEMs. We report for the
first time that macrophage depletion is associated with increased macrophage progenitors in bone
marrow. Furthermore, T-PEMs have a lower expression of macrophage differentiation markers F4/80,
CD68, CD115, and CD11b, whereas Gr-1 is up-regulated. Our results suggest that T-PEMs are less
differentiated and represent a newly derived population from blood monocytes. Lastly, we show that
transforming growth factor-beta and prostaglandin E(2), two immunosuppressive tumor-derived factors,
may be involved in this phenomenon.
Identification of a Subpopulation of Macrophages in Mammary
Tumor–Bearing Mice That Are Neither M1 nor M2
and Are Less Differentiated
Marta Torroella-Kouri,
1,2
Risset Silvera,
1
Dayron Rodriguez,
1
Raul Caso,
1
Alwi Shatry,
1
Shannon Opiela,
2
Dan Ilkovitch,
1
Reto A. Schwendener,
4
Vijaya Iragavarapu-Charyulu,
3
Yoslayma Cardentey,
2
Natasa Strbo,
1
and Diana M. Lopez
1,2
1Department of Microbiology and Immunology, University of Miami School of Medicine, 2Sylvester Cancer Center,
Miami, Florida; 3Department of Biomedical Sciences, Florida Atlantic University, Boca Raton, Florida; and
4Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland
Abstract
Systemic and local immune deficiency is associated with
cancer, and the role of M2 tumor-associated macrophages in
this phenomenon is well recognized. However, the immune
status of macrophages from peripheral compartments in
tumor hosts is unclear. Peritoneal macrophages (PEM) are
derived from circulating monocytes and recruited to the
peritoneal cavity where they differentiate into macrophages.
We have previously shown that PEMs from mice bearing
D1-DMBA-3 mammary tumors (T-PEM) are deficient in
inflammatory functions and that this impairment is associat-
ed with diminished expression of transcription factors nuclear
factor KB and CAAT/enhancer-binding protein. We now
provide evidence that T-PEMs display neither M1 nor M2
phenotypes, yet exhibit deficiencies in the expression of
several inflammatory cytokines and various proinflammatory
signaling pathways. Moreover, due to nuclear factor KB down-
regulation, increased apoptosis was observed in T-PEMs. We
report for the first time that macrophage depletion is
associated with increased macrophage progenitors in bone
marrow. Furthermore, T-PEMs have a lower expression of
macrophage differentiation markers F4/80, CD68, CD115, and
CD11b, whereas Gr-1 is up-regulated. Our results suggest that
T-PEMs are less differentiated and represent a newly derived
population from blood monocytes. Lastly, we show that
transforming growth factor-B and prostaglandin E2, two
immunosuppressive tumor-derived factors, may be involved
in this phenomenon. [Cancer Res 2009;69(11):4800–9]
Introduction
Systemic immune deficiency in cancer (1–3) and the occurrence
of a local immune suppression within tumors (4, 5) have been well
documented. Indeed, tumor-associated macrophages (TAM),
myeloid-derived suppressor cells (MDSC) and some T-cell subsets
colonizing the tumor microenvironment exhibit immunosuppres-
sive properties. However, the contribution of macrophages from
extra-tumor sites to the host immune competence has received less
attention.
Circulating monocytes differentiate into macrophages upon
entry into tissues. Macrophages (6) produce inflammatory
cytokines to activate the adaptive immune system and aid in the
elimination of microbes and tumor cells. When tissue damage is
unresolved, chronic inflammation establishes (7). In this scenario,
macrophages continue to exhibit proinflammatory features and
generate tissue damage indefinitely.
Two opposite polarization states have been described for
macrophages depending on their immune competence: the
classically activated M1 and the alternatively activated M2 (5).
The M1 macrophage is proinflammatory and is induced by IFN-g
alone or together with microbial stimuli (i.e., LPS). They present
antigens efficiently, produce high levels of proinflammatory
cytokines such as interleukin (IL)-12, are efficient activators of
Th1 T-cell responses, and are cytotoxic against microbes and tumor
cells. M1 macrophages are thus considered powerful effectors
against the attack of pathogens and tumor cells. M2 macrophages,
in contrast, are induced by IL-4 and IL-13, immune complexes, IL-10
or glucocorticoids. They possess less efficient antigen-presenting
capacity, have an IL-12lowIL-10high phenotype, suppress Th1
immunity, and promote wound healing, tissue remodeling, and
angiogenesis. Thus, M2 macrophages play a role in the homeostatic
mechanisms that terminate inflammatory responses.
Substantial experimental and epidemiologic evidence links
chronic inflammation with cancer (7, 8). Macrophages are involved
both in initial and later stages of carcinogenesis, paralleling the
interplay between inflammation and cancer in their switch from
activated M1 in inflamed tissues to M2 tumor-promoting,
proangiogenic TAMs (5, 9).
Peritoneal macrophages (PEM) are derived from circulating
monocytes and represent peripheral cells exposed to the circula-
tion in the peritoneal cavity. In contrast, TAMs differentiate within
the immunosuppressive tumor microenvironment. We have shown
that macrophages from mice bearing advanced D1-DMBA-3
mammary tumors (T-PEM) function less efficiently as antigen-
presenting cells compared with macrophages from normal animals
(N-PEMs; ref. 10) and produce low levels of IL-12 and nitric oxide
(11, 12). Moreover, a deficiency in proinflammatory functions is
associated with decreased expression of transcription factors
nuclear factor nB (NFnB) and CAAT/enhancer-binding protein
(C/EBP) in these cells (13). We now provide evidence that T-PEMs
are neither M1 nor M2, are more prone to apoptosis, and express
lower levels of macrophage differentiation markers. Furthermore,
we show for the first time that macrophage depletion is associated
with enhanced generation of macrophage precursors in the bone
marrow.
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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Materials and Methods
Animals, cell lines, and tumors. BALB/c mice, 10 to 14 weeks of age,
were used. D1-DMBA-3 mammary adenocarcinoma and DA-3 mammary
tumor cell line, derived from D1-DMBA-3, were maintained and used as
previously described (14, 15). Lewis lung carcinoma (LLC), Renca renal cell
carcinoma, 4T1mammary carcinoma, andmouse fibroblast 3T3 cell lines were
kindly provided by Eckhard Podack (University of Miami, Miami, FL). The
institutional animal care and use committee approved the animal experiments.
Macrophage collection and culture. Normal and 4-wk tumor-bearing
mice were injected i.p. with 1.5 mL of 3% thioglycolate (Difco Laboratories).
On day 4, PEMs were obtained and cultured as described (13).
Laser confocal microscopy. Macrophages were adhered to glass
slides and Fc receptors blocked using mouse CD16/32 antibody
Figure 1. NFnB and C/EBP are down-regulated in T-PEMs. A, confocal images of N-PEMs and T-PEMs stained with NFnBp50-PE and NFnBp65-PE (red ) and
with DAPI (blue ). B, NFnBp105, RelA, and c-Rel mRNA levels in N-PEMs and T-PEMs were determined by real-time PCR using 18S for normalization. C, gene
expression array and densitometry shows C/EBPh mRNA expression in N-PEMs and T-PEMs using h-actin for normalization. D, Western blot of NFnB and C/EBP
expression in N-PEMs and T-PEMs isolated from Renca and 4T1 tumor-bearing mice.
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Figure 2. Proinflammatory cytokines and various signaling intermediates are down-regulated in T-PEMs. N-PEMs and T-PEMs were isolated and cultured without (B) and
with 10 Ag/mL of LPS (for 20 h in A , and for 1 h in D) before obtaining whole cell extracts. A, left, antibody array histogram showing densitometry after adjustment
with a positive control of inflammatory cytokines produced by LPS-stimulated N-PEMs and T-PEMs. Right, cell viability assessment using DAPI and PI of N-PEMs and
T-PEMs stimulated with LPS for 20 h.Pink, dead cells (PI+).B, Western blot and densitometry after h-actin adjustment of MyD88, IRAK-1, and IRAK-M expression in resting
N-PEMs and T-PEMs. C, gene expression array and densitometry from N-PEM and T-PEMs shows ERK1/2, p38, JNK, and NIK mRNA expressions after h-actin
normalization. D, left, Western blot and densitometry normalized with h-actin of STAT1/pSTA1 and STAT3/pSTA3 expression of resting and LPS-stimulated N-PEMs and
T-PEMs. Right, CXCL10 mRNA levels in resting and LPS-stimulated N-PEMs and T-PEMs were determined by real-time PCR using 18S for normalization.
Cancer Research
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(eBioscience). Cells were washed, fixed with 10% formalin, permeabilized
with Optimax permeabilization buffer (Sigma-Aldrich) and then incubated
with 4¶,6-diamidino-2-phenylindole (DAPI; Invitrogen) to reveal nuclei.
For intracellular NFnB staining, fixed and permeabilized macrophages
were incubated with NFnBp50-PE and NFnBp65-PE (Santa Cruz Biotech-
nologies) or with the corresponding isotype control. Fixed cells were
then stained with F4/80PE-Cy7 (BioLegend), CD11b-AF488 and
Gr-1-AF647 (eBioscience), incubated with DAPI, and then mounted.
Slides were analyzed using a Zeiss laser scanning confocal microscope
500 (Zeiss).
Flow cytometry. N-PEMs and T-PEMs were gently scraped from
tissue culture plates, washed, and counted. Fc receptors were blocked
Figure 3. Increased apoptosis in T-PEMs and augmentation of committed myeloid progenitors in the marrow of tumor bearers. A, left, Western blot and densitometry after
normalization with h-actin of Bcl-x expression in N-PEMs and T-PEMs. Right, colorimetric TUNEL assay of N-PEMs and T-PEMs. B, Western blot analysis and
densitometry after normalization with h-actin of activated caspase 3 in N-PEMs and T-PEMs. Lanes 1 to 3, N-PEMs cultured with 0, 10, and 100 nmol, respectively, of
staurosporine for 2 h; lane 4, untreated T-PEMs cultured for the same amount of time. C, CFU-IL-3 and CFU-M-CSF assays were performed on marrow cells from
normal or tumor-bearing mice. Cells were cultured with rmIL-3 (50 units/mL) and M-CSF (20 ng/mL). D, top, F4/80 flow cytometry of resident PEMs from PBS and
Clodrolip-treated normal mice. Bottom, CFU analysis of IL-3 and M-CSF–induced myeloid progenitors in marrow from control and Clodrolip-treated mice.
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and cells were stained with CD11b-FITC, CD115-PE, Gr-1-APC antibodies
(all from eBioscience), and F4/80-PE Cy7 (BioLegend). Intracellular
staining for CD68-AF700 (AbD Serotec) was performed following the
instructions of the manufacturer. To assess viability, cells were stained with
7-amino-actinomycin D (7-AAD; BD PharMingen), which was added 15 min
prior to analyzing by flow cytometry. Samples were acquired in a LSR II
cytometer (BD Biosciences).
Committed progenitor assay. Colony-forming unit (CFU) assays using
stimulation with IL-3 or M-CSF (Peprotech) were performed (16). Single
clusters containing more than 50 cells were counted as a colony. Results are
expressed as CFU-IL-3 and CFU-M-CSF per 106 cells plated.
Real-time PCR. PEMs (107 cells) from individual normal and tumor–
bearing animals were cultured in complete medium without LPS (NFnB
experiments) or with 10 Ag/mL of LPS for 2 h (CXCL10 experiments). Total
RNA was isolated and cDNA synthesis was performed (1 Ag total RNA)
using Invitrogen reagents according to the manufacturer’s instructions.
Real-time or quantitative PCR was done using TaqMan Gene Expression
Assays for NFnBp105, relA, c-rel, CXCL10, and eukaryotic 18S RNA on a 7500
Fast Real-time PCR system from Applied Biosystems following the
instructions of the manufacturer.
cDNA arrays. Relative mRNA expression was analyzed by microarray
technology using the mouse JAK/signal transducer and activation of
transcription (STAT) signaling pathway (MM-039) and the mouse mitogen-
activated protein kinase (MAPK) signaling pathway (MM-017; GE Array
Q Series, SuperArray, Inc.), using total RNAs isolated from N-PEMs and
T-PEMs as previously described (17).
Antibody array. The Mouse Inflammation Antibody Array 1.1 (RayBio-
tech, Inc.) was used to study the expression of proinflammatory cytokines in
whole cell lysates from LPS-activated (Sigma-Aldrich) N-PEM and T-PEMs,
following the manufacturer’s instructions.
TUNEL assay. The DeadEnd Colorimetric Terminal uridine deoxynu-
cleotidyl transferase dUTP nick end-labeling or TUNEL System from
Promega was performed according to the manufacturer’s instructions, using
resting N-PEM and T-PEM.
Western blot. N-PEM and T-PEM (107) were adhered to plastic tissue
culture dishes, whole cell extracts were obtained, and Western blot was
performed as previously described (13). Rabbit a-mouse polyclonal antibodies
(except for IRAK-M, a goat anti-mouse polyclonal antibody) from Santa Cruz
Biotechnologies were used as the primary antibody. Anti–Bcl-x was kindly
provided by Dr. Larry Boise (Department of Microbiology and Immunology,
University of Miami School of Medicine, Miami, FL; ref. 18), and staurosporine
was from EMD Biosciences. Rabbit a-mouse STATand phosphorylated STAT
(STAT1 and STAT3) antibodies and a-caspase 3 antibody were from Cell
Signaling Technologies. Rabbit a-mouse actin polyclonal antibody was
obtained from Sigma-Aldrich. Goat a-rabbit IgG-HRP, except for the IRAK-
M (rabbit a-goat IgG-HRP) was used as the secondary antibody. In some
experiments, N-PEMs were pretreated with phosphatidylserine (Avanti Polar
Lipids), transforming growth factor-h (TGFh), vascular endothelial growth
factor (VEGF), prostaglandin E2 (PGE2), granulocyte macrophage colony-
stimulating factor, and IL-11 (all from Peprotech).
Macrophage depletion using liposome-encapsulated clodronate
(Clodrolip). Normal mice were injected i.p. with 1 and 2 mg/20 g weight
Figure 4. T-PEMs express an immature
phenotype. A, flow cytometric analysis of
CD11b, F4/80, CD68, CD115, and Gr-1 in
resting N-PEMs and T-PEMs (right, MFI
values). B, Diff-Quick staining reveals the
morphology of N-PEMs and T-PEMs. C,
similar phenotypic analysis as in A was
performed on 7-AAD cells (viable cells).
Cancer Research
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of Clodrolip (sodium-clodronate tetrahydrate; Farchemia; ref. 19)
or equivalent volumes of PBS (three mice/treatment) and sacrificed
after 24 and 48 h. PEMs were analyzed for the presence of F4/80+
macrophages by flow cytometry and bone marrow cells were processed for
CFU assays.
Treatment of macrophages with conditioned medium from tumor
cell lines and with recombinant tumor factors. Cell line–conditioned
medium from 4-d cultures was centrifuged and supernatants were frozen at
80jC. Recombinant tumor-derived factors were prepared just before use.
N-PEMs (107) were adhered to plastic tissue culture dishes and cultured for
20 h in complete medium containing 50% and 80% of tumor cell line
supernatants or recombinant tumor-derived factors. Cells were lysed and
Western blot analysis was performed.
Statistical analysis. Paired t test was used to analyze statistical
significance, and error bars represent SEM.
Results
T-PEMs express diminished levels of NFKB and C/EBP at
mRNA and protein levels. Our previous studies using Western
blot and EMSA revealed that resting and LPS-activated T-PEMs
exhibit decreased levels and binding activities of transcription
factor proteins NFnBp50, p65, c-rel, and C/EBPa and C/EBPh (13).
Down-regulation of NFnBp50 and p65 proteins in these cells was
confirmed using intracellular staining and laser confocal micros-
copy (Fig. 1A). We examined whether NFnB down-regulation was
also reflected at the mRNA levels in T-PEMs. Real-time PCR
confirmed that the mRNAs encoding for NFnBp50, p65, and c-rel
proteins are down-regulated in T-PEMs (Fig. 1B). Moreover, gene
microarray experiments (Fig. 1C ; C/EBPa was not assessed in the
microarray) corroborated the decreased levels of C/EBPh tran-
scription factor protein in T-PEMs, which we have previously
described (13). These results suggest that the factors responsible
for NFnB and C/EBP diminished expression in T-PEMs may act
through transcriptional or posttranscriptional mechanisms. To
analyze whether this might be a more general mechanism existing
in T-PEMs, we studied the protein expression of NFnB and C/EBP
in T-PEMs from other mouse tumor models. Our results (Fig. 1D),
using T-PEMs from mice bearing Renca renal cell carcinomas and
4T1 mammary tumors, confirm the decreased protein expression
of NFnB and C/EBP in these models.
T-PEMs are defective in the production of several proin-
flammatory cytokines. A major factor contributing to proin-
Figure 5. Supernatants from tumor
cell lines mimic N-PEMs decreased
expression of NFnB and C/EBP
observed in T-PEMs. A, Western blot
of NFnBp50, p65, c-rel, C/EBPa, and
C/EBPh expression in N-PEMs and
T-PEMs. B, Western blot and
densitometry after h-actin adjustment
of NFnB and C/EBP expression in
N-PEMs cultured for 20 h in complete
medium or with 50% and 80% of cell
culture supernatants from the DA-3 (B),
LLC (C), and 3T3 fibroblast cell
lines (D).
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flammatory impairment in T-PEMS is their diminished expression
of NFnB and C/EBP. We thus hypothesized that in addition to IL-12
and nitric oxide synthase (iNOS), other inflammatory molecules
transcriptionally regulated by NFnB may also be down-regulated in
T-PEMs. Protein microarray analysis (Fig. 2A) using cell lysates of
LPS-activated N-PEMs and T-PEMs revealed that T-PEMs, in
addition to IL-12, are deficient in the production of IL-1h, IL-6,
tumor necrosis factor-a, MCP-1, and M-CSF. Interestingly, LPS-
activated T-PEMs did not up-regulate expression of the anti-
inflammatory cytokine IL-10 compared with N-PEMs (13). Cell
viability of cultured N-PEMs and T-PEMs as determined by DAPI
and PI showed no significant lethality (PI+ cells) in either cell type
upon cell culture (Fig. 2A).
IRAK-1, NIK, and critical MAPK are reduced, whereas IRAK-
M is increased in T-PEMs. Because different signaling pathways
are involved in the control of cytokine expression, we analyzed
other proinflammatory signaling pathways in T-PEMs. Several
crucial intermediates operate upstream of NFnB in the Toll-like
receptor/NFnB signaling pathway. Although MyD88 and IRAK-1
are important in the signaling cascade triggered by activation
of Toll-like receptors on the cell surface (20), IRAK-M is an
inhibitor of this pathway (21). Analysis of the protein expression
of these intermediates in T-PEMs showed that, although there
are no significant changes in the expression of MyD88 in T-PEMs,
kinase IRAK-1 is dramatically diminished whereas the inhibitor
kinase IRAK-M is up-regulated in T-PEMs (Fig. 2B). Because
MAPKs also play an important role in the regulation of
proinflammatory cytokine gene expression (22), their levels were
analyzed in T-PEMs. Gene microarray analysis using total RNA
obtained from N-PEMs and T-PEMs showed a general decrease in
the mRNA expression of most of the MAPKs examined (Fig. 2C).
Furthermore, a substantial reduction of NIK (NFnB-inducing
kinase), JNK, p38, and ERK1/2 gene expression was observed.
These data indicate major dysfunctional signaling in several
pathways of proinflammatory cytokines in T-PEMs.
STAT1, but not STAT3, is down-regulated in T-PEMs. STATs
are transcription factors that regulate many aspects of cell growth,
survival, and differentiation. STAT1 is involved in up-regulating
genes upon stimulation by IFNs, and is associated with the
activation of a Th1-type of antitumor immune response (23). In
contrast, STAT3 is overexpressed in tumor cells and is an
antiapoptotic factor that leads to tumor tolerance in the host
(24). Up-regulation of the STAT3 pathway leads to increased
angiogenesis, tumor survival, and immunosuppression (25). We
investigated whether T-PEMs exhibit altered expression of STAT1
and STAT3. Because these transcription factors are activated by
phosphorylation, the expression of both their resting and activated
(phosphorylated) forms was compared in N-PEMs and T-PEMs
Figure 6. DA-3–derived TGFh and PGE2
induce decreased expression of NFnB
and C/EBP in N-PEMs. Western blot
analysis of NFnB and C/EBP expression:
A, N-PEMs treated for 20 h with increasing
concentrations of TGFh (0, 50, and
105 pg/mL), PGE2 (0, 1, and 360 ng/mL),
and VEGF (0, 1,700, and 105 pg/mL);
B, PGE2 and TGFh individually or in
combination. Histograms in B show
densitometry after h-actin adjustment.
Cancer Research
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using Western blot analysis. As seen in Fig. 2D , STAT1 is down-
regulated in resting as well as LPS-activated T-PEMs. Accordingly,
these cells also exhibit reduced STAT1 phosphorylation upon LPS
activation compared with their normal counterparts. Interestingly,
the levels of STAT3 or pSTAT3 were similar in the two cell types.
We examined whether STAT1-regulated genes were also affected.
Thus, the expression of the chemokine CXCL10 in LPS-stimulated
N-PEMs and T-PEMs was determined. Real-time PCR analysis
showed decreased CXCL10 mRNA expression in LPS-stimulated
T-PEMs (Fig. 2D).
T-PEMs express low levels of Bcl-x and high levels of acti-
vated caspase 3 and are more apoptotic. NFnB, in addition to
promoting the described pathways, also induces the expression
of several antiapoptotic genes such as Bcl-x. Using Western blots
(Fig. 3A), a substantial down-regulation in Bcl-x protein expres-
sion was observed in resting T-PEMs. Furthermore, TUNEL assays
confirmed higher levels of apoptosis in T-PEMs, and apoptotic nuclei
in these cells were pyknotic and fragmented (Fig. 3A). Activation
of caspase 3 is crucial for apoptosis. Thus, we determined whether
the increased apoptosis was associated with higher levels of
activated caspase 3 in T-PEMs compared with N-PEMs. Treat-
ment with increasing concentrations of staurosporine, an apoptosis-
inducing agent, was included as a positive control of caspase 3
activation in N-PEMs. Results showed an increase in the basal
expression of the 17 to 19 kDa bands (activated caspase 3) in
T-PEMs, even at higher levels than those observed in staurosporine-
treated N-PEMs, indicating caspase 3 activation and thus apoptosis
execution in T-PEMs (Fig. 3B). Consequently, T-PEMs are not only
dysfunctional but may be less frequent because of their greater
susceptibility to apoptosis.
Macrophage apoptosis in the periphery is associated with
increased myeloid progenitors in the bone marrow of tumor-
bearing mice. Because our results suggest that the tumor induces
decreased NFnB expression and enhanced apoptosis in T-PEMs, a
compensatory increase in the generation of myeloid progenitors
may be occurring in the bone marrow of tumor bearers. Thus,
functional CFU assays for marrow-derived myeloid progenitors
from normal and tumor-bearing mice were carried out using IL-3
and M-CSF. Our results confirm that the numbers of different
myeloid progenitors are significantly increased in tumor hosts
when compared with normal mice (Fig. 3C). To determine whether
decreased numbers of peripheral macrophages contribute to the
induction of marrow myelopoiesis, normal mice were treated with
i.p. injections of Clodrolip, a macrophage-depleting agent (19).
Flow cytometry analyses showed that treatment of normal mice
with 1 or 2 mg of Clodrolip ( for 24 and 48 hours) significantly
depleted F4/80+ resident PEMs, compared with PBS-treated
animals at all dose combinations (Fig. 3D). Importantly, marrow
cells from these macrophage-depleted animals exhibited signifi-
cantly enhanced production of CFU-M-CSF but not CFU-IL-3–
induced myeloid progenitors after treatment with Clodrolip for 48
hours. Thus, 48 hours of macrophage depletion was sufficient to
induce myelopoiesis in the bone marrow (Fig. 3D). These results
suggest that macrophage depletion is associated with a specific
increase in marrow progenitors committed to macrophage but not
other myeloid lineages.
T-PEMs down-regulate expression of F4/80, CD68, CD115,
and CD11b and up-regulate Gr-1. Macrophages normally express
the myeloid markers F4/80, CD68, CD115 (M-CSF receptor), and
CD11b, and the elevated expression of these molecules is
considered indicative of macrophage differentiation (26, 27).
T-PEMs express significantly lower levels of F4/80, CD68, CD115,
and CD11b than N-PEMs (Fig. 4A), consistent with the phenotype
of newly recruited blood monocytes (F4/80low CD68lowC-
D115lowCD11blow). These results suggest that T-PEMs are
less-differentiated than N-PEMs. Interestingly, T-PEMs also exhibit
up-regulation of the granulocytic myeloid marker Gr-1. Yet, they
appear as a homogeneous cell population of macrophages of larger
size and increased vacuolation (Fig. 4B). As T-PEMs are prone to
apoptosis, 7-AAD viability marker was included in our flow
cytometric experiments. Similar to Fig. 4A , expression of macro-
phage markers was decreased whereas Gr-1 expression was
increased on viable (7-AAD) T-PEMs (Fig. 4C).
In vitro pretreatment of N-PEMs with supernatants from
tumor cell lines mimics the reduced expression of NFnB and
C/EBP observed in T-PEMs. Because the presence of advanced
mammary tumors results in a profound decrease in expression of
NFnB and C/EBP at the gene and protein levels in T-PEMs, we
investigated whether ex vivo pretreatment of N-PEMs with
supernatants collected from 4-day-old cultures of the DA-3 cell
line produced similar effects. Figure 5A shows diminished
expression of NFnB and C/EBP proteins in T-PEMs as a positive
control to compare with the effect of the in vitro treatment of
N-PEMs with tumor supernatants. Culturing N-PEMs with
increasing concentrations of DA-3 cell supernatant induced
reductions in the amounts of some NFnB and C/EBP proteins in
these macrophages (Fig. 5B). To assess whether NFnB and C/EBP
down-regulation is associated with tumor-secreted factors, N-PEMs
were pretreated with supernatants from different cell lines.
Pretreatment of N-PEMs with supernatants from the tumorigenic
LLC cell line down-regulated the expression of NFnB and C/EBP
(Fig. 5C), whereas N-PEMs pretreated with supernatants from the
nontumorigenic 3T3 cell line did not (Fig. 5D), implicating factors
secreted by tumor cell lines in NFnB and C/EBP down-regulation.
Cell viability of N-PEMs cultured with 80% of DA-3 and LLC cell
supernatants was assessed by PI staining. No significant toxicity
(increased numbers of PI+ cells) was observed in these treated
cells (Supplemental Fig. S1). Furthermore, expression of F4/80,
CD11b, and Gr-1 did not change significantly when N-PEMs were
cultured with LLC supernatants compared with untreated N-PEMs
(Supplemental Fig. S2).
TGFB and PGE2 tumor factors are associated with the
diminished expression of NFKB and C/EBP observed in
T-PEMs. The DA-3 tumor cell line secretes several factors
(1, 15, 28, 29) which are also produced by other tumors (30, 31).
Pretreatment of N-PEMs with tumor-derived factors results in
diminished expression of IL-12 and of iNOS (11, 32). To examine
whether some of these tumor-derived factors might be associated
with the impairment of NFnB and C/EBP expression observed in
T-PEMs, resting N-PEMs were pretreated with increasing concen-
trations of these tumor-derived products. Pretreatment of N-PEMs
with increasing concentrations of TGFh and PGE2 resulted in a
substantial decrease in NFnB and C/EBP expression in these cells
(Fig. 6A). However, the addition of phosphatidylserine, GM-CSF, or
IL-11 did not alter their expression (data not shown). Interestingly,
pretreatment of N-PEMswith VEGF resulted in enhanced expression
of NFnB and C/EBP. To study the possible interactions between
TGFh and PGE2 that might occur within macrophages in vivo ,
we pretreated N-PEMs with these tumor factors simultaneously.
Our results show that these two tumor factors operate in a
synergistic fashion to decrease the expression levels of NFnB and
C/EBP (Fig. 6B).
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Discussion
Macrophages are plastic in that their phenotype changes to
adapt to their environment (33). Our unpublished data confirm
that TAMs from mammary D1-DMBA-3 tumor bearers are classic
M2 macrophages, with IL-12low and IL-10high. The immune
competence of T-PEMs was examined and there was evidence
that these cells, which reside in a nontumor location, are not M2
suppressors, they are IL-12low, but are not IL-10high. No enhanced
expression of other suppressor markers shared by M2 macro-
phages was detected (34, 35), such as higher expression of VEGF,
matrix metalloproteinase-9, or arginase (data not shown). We
have previously shown that T-PEMs do produce elevated levels of
the suppressor cytokine TGFh (29). We now provide evidence that
these cells display a mixed phenotype (neither M1 nor M2), with
down-regulation of several proinflammatory signaling pathways
and cytokine production. Potent levels of circulating tumor
factors may interact with T-PEMs, leading to such a phenotype.
Immune modulation may occur in the circulation when they are
still monocytes, or perhaps during their differentiation to
macrophages in the peritoneal cavity. The fact that both NFnB
and C/EBP are constitutively decreased in these cells results in
their deficiency to produce inflammatory cytokines and chemo-
kines, such as IL-12, IL-6, tumor necrosis factor-a, IL-1h, M-CSF,
and MCP-1 (36, 37). Furthermore, the down-regulation of NIK
mRNA in resting T-PEMs and the involvement of this kinase in
both the classic (38) and the alternative (39) NFnB activation
pathways, together with the deficiency of T-PEMs in p38, JNK,
and ERK, indicate critical impairments in NFnB and related
signaling pathways in these cells. STAT1, another crucial signaling
mediator of Th1 immunity, is also impaired in T-PEMs. Resting or
LPS-activated T-PEMs exhibit lower levels of STAT1 and pSTAT1
expression compared with N-PEMs. Moreover, the STAT1-induced
gene CXCL10 was also down-regulated at the mRNA level. In
contrast with our results in T-PEMs, increased phosphorylation of
STAT1 has been observed in TAMs (40).5 Kusmartsev and
Gabrilovich have also described elevated STAT1 in TAMs, which
they associate with an up-regulation of iNOS and arginase activity
in these cells (41). In this respect, we have reported that T-PEMs
and TAMs in our tumor model have very low iNOS expression
(12), and in the present study, no differences in arginase
production between N-PEMs and T-PEMs were observed (data
not shown). This suggests a mixed phenotype displayed by
T-PEMs, presenting some characteristics of M1 macrophages and
only some of the M2-suppressive traits. Furthermore, the patterns
of cytokine expression displayed by T-PEMs provide functional
evidence that these cells are different from M1 and M2
macrophages. Remarkably, T-PEMs are not fixed in their mixed
M1/M2 phenotype, and can become high producers of IL-12 or of
IL-10. T-PEMs can be experimentally switched to express high
amounts of IL-12p70 by culturing in the presence of LPS and
IFN-g. Moreover, they can be induced to produce elevated
amounts of IL-10 by culturing them with peptidoglycan, a Toll-
like receptor 2 ligand (Supplemental Fig. S3).
We sought to examine the possibility of enhanced apoptosis
in T-PEMs, as a consequence of their decreased NFnB. Results
indicate that resting T-PEMs express dramatically diminished
levels of NFnB-induced antiapoptotic Bcl-x, enhanced activated
caspase-3, and increased apoptosis. Importantly, apoptotic cells
such as T-PEMs may still be PI in early apoptotic stages and
thus detected as ‘‘viable’’ macrophages due to intact membranes.
To analyze whether apoptosis could induce the marrow of
tumor-bearing mice to compensate for the loss of macrophages
in the periphery by generating higher numbers of myeloid
progenitor cells, bone marrow from normal and tumor-bearing
mice were compared using CFU assays specific for committed
myeloid progenitors. Our data show that the frequency of
committed myeloid progenitors for either a broad spectrum of
myeloid cell types (IL-3) or specific for the monocyte‘s/macro-
phage’s lineage (M-CSF) are both significantly augmented in
tumor-bearing mice. Increased myelopoiesis in the marrow of
tumor–bearing mice has been associated with tumor factors
(42, 43). However, we show for the first time that a decrease
in macrophage numbers, in the absence of a tumor, can also
induce marrow myelopoiesis. Furthermore, macrophage-depleted
mice show myelopoiesis which specifically replenishes cells of
the macrophage lineage. Compensatory homeostasis due to
increased macrophage apoptosis could be an additional
contributing factor to the increased myelopoiesis observed in
tumor bearers.
The migration of newly produced monocytes from bone
marrow to the circulation could result in macrophages with an
immature phenotype. Thus, we compared the phenotype of
T-PEMs with that of N-PEMs. Flow cytometry analysis revealed
significantly decreased expression of F4/80, CD68, CD115, and
CD11b in T-PEMs, all markers of macrophage differentiation.
Interestingly, these cells express the granulocyte marker Gr-1 at
higher levels than N-PEMs. Gr-1 is considered a marker of
neutrophils and of immunosuppressive MDSC, which are CD11b+/
Gr-1+ (44). CD68+/Gr-1+ macrophages have been described in the
peritoneal cavity of mice infected with low doses of Toxoplasma
gondii ; these macrophages also express CD11b and F4/80 but at
lower levels than PEMs from uninfected mice (45). Gr-1 is also
expressed by immature TAMs thought to function in immuno-
suppression (46). Our T-PEMs do not express characteristic
markers of MDSC, such as arginase and/or nitric oxide (15). In
contrast to our T-PEMs, splenic MDSCs isolated from DA-3-
tumor–bearing mice do not express F4/80 (47). Our data suggest
that T-PEMs are a less differentiated cell population and thus
represent recently recruited monocytes from the blood that may
become apoptotic during differentiation into macrophages. The
fact that T-PEMs are less differentiated may also contribute to
their highly plastic behavior.
We sought to determine whether tumor-derived factors were
associated with the changes observed in T-PEMs. Our results
show that factors secreted by DA-3 and LLC decreased NFnB
and C/EBP expression in N-PEMs. Indeed, TGFh and PGE2,
individually and additively induced down-regulation of NFnB
and C/EBP family members. Interestingly, pretreatment with
VEGF induced elevated levels of NFnB and C/EBP in N-PEMs,
in sharp contrast to our data with T-PEMs. VEGF levels that
circulate in tumor bearers may not be sufficient to increase
NFnB and C/EBP in T-PEMs, or alternatively, VEGF might
interact with other factors in vivo which block the induction of
NFnB and C/EBP.
Tumors produce immunomodulatory factors in excess, which
may thus alter immune function both locally at the tumor site and
systemically. Reversing tumor-induced immune function in cancer
patients may be carried out by targeting impaired immune cells.5 Our unpublished results.
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One possibility is to re-educate M2 TAMs or mixed phenotype
M1/M2 T-PEMs to become antitumor M1s. Augmenting NFnB
expression may be one approach, as peripheral macrophages as
well as TAMs from various tumor models exhibit down-regulated
NFnB (48).6
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